Literature DB >> 1729256

Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

S H de Bie, T C Ferreira, E K Pauwels, F J Cleton.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1729256     DOI： 10.1007/bf01192305

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  118 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor.

Authors:  I F Tannock
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

3.  Differences in biodistribution of indium-111-and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer.

Authors:  K Yokoyama; J A Carrasquillo; A E Chang; D Colcher; M Roselli; P Sugarbaker; W Sindelar; J C Reynolds; P Perentesis; O A Gansow
Journal:  J Nucl Med       Date:  1989-03       Impact factor: 10.057

4.  Dual isotope study of iodine-125 and indium-111-labeled antibody in athymic mice.

Authors:  P L Carney; P E Rogers; D K Johnson
Journal:  J Nucl Med       Date:  1989-03       Impact factor: 10.057

5.  Limitations to the killing of tumours using radiolabelled antibodies.

Authors:  A T Vaughan; P Anderson; P W Dykes; C E Chapman; A R Bradwell
Journal:  Br J Radiol       Date:  1987-06       Impact factor: 3.039

6.  Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody.

Authors:  R H Begent; P A Keep; A J Green; F Searle; K D Bagshawe; R F Jewkes; B E Jones; G M Barratt; B E Ryman
Journal:  Lancet       Date:  1982-10-02       Impact factor: 79.321

7.  Stability, characterization, and kinetics of 111In-labeled monoclonal antitumor antibodies in normal animals and nude mouse-human tumor models.

Authors:  S E Halpern; P L Hagan; P R Garver; J A Koziol; A W Chen; J M Frincke; R M Bartholomew; G S David; T H Adams
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

8.  Comparative tumour localization properties of radiolabelled monoclonal antibody preparations of defined immunoreactivities.

Authors:  M V Pimm; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1987

9.  Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody.

Authors:  J A Carrasquillo; P A Bunn; A M Keenan; J C Reynolds; R W Schroff; K A Foon; M H Su; A F Gazdar; J L Mulshine; R K Oldham
Journal:  N Engl J Med       Date:  1986-09-11       Impact factor: 91.245

10.  Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation.

Authors:  J P Mach; S Carrel; M Forni; J Ritschard; A Donath; P Alberto
Journal:  N Engl J Med       Date:  1980-07-03       Impact factor: 91.245
View more
  4 in total

1.  Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy.

Authors:  C Somasundaram; S Matzku; J Schuhmacher; M Zöller
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

2.  Radioimmunotherapy: no news from the newcomer.

Authors:  A M Mello; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

3.  Technetium-99m antimyosin antibody (3-48) myocardial imaging: human biodistribution, safety and clinical results in detection of acute myocardial infarction.

Authors:  R Taillefer; L Boucher; R Lambert; J Grégoire; D C Phaneuf; H Sikorsa
Journal:  Eur J Nucl Med       Date:  1995-05

4.  Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay.

Authors:  S C Henzen-Logmans; E M Berns; J G Klijn; M E van der Burg; J A Foekens
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.